Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national …
Bristol Myers Squibb and A.C.Camargo Cancer Center signed BMS’s first oncology risk-sharing agreement in Brazil, covering first-line ipilimumab plus nivolumab in lung cancer, with results assessed within 90 days of …
For every peso the Mexican state spends on health, patients pay 0.85 out of pocket. In Colombia they pay 0.21. Who funds health care in six major Latin American markets, …
Prati-Donaduzzi is committing R$1 billion, about 40% of its 2025 revenue, to a new 5-billion-dose solid-dose plant in Paraná as it pushes toward international markets.
Panama has installed the National System of Reference Prices for Medicines (SINPREM), a system created by Law 419 of 2024 that pools the drug needs of the Ministry of Health …
Costa Rica’s social security fund is running technical studies to choose a GLP-1 molecule for patients with diabetes, with obesity to follow. A diabetes decision is expected in November, as …
The US Department of Labor finalized a rule on October 29, 2026 requiring pharmacy benefit managers to disclose rebates, spread compensation and other payments to large self-insured employer plans. It …
Phase III SAFFRON data show osimertinib plus savolitinib cut progression or death risk by 45% and death risk by 32% versus chemotherapy in MET-driven epidermal growth factor receptor-mutated non-small cell …
Phase III DeLLphi-305 data show tarlatamab plus durvalumab extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone in extensive-stage small cell lung cancer maintenance.
CMS has finalized GLOBE, a mandatory most-favored-nation rebate model for high-spend Medicare Part B drugs starting January 1, 2027. It is far narrower than proposed, faces a PhRMA lawsuit, and …
You must be logged in to post a comment.